Financials data is unavailable for this security.
View more
Year on year Orion Oyj 's revenues fell -11.26% from 1.34bn to 1.19bn. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from 349.50m to 216.80m, a -37.97% decrease.
| Gross margin | 59.89% |
|---|---|
| Net profit margin | 23.19% |
| Operating margin | 29.16% |
| Return on assets | 22.25% |
|---|---|
| Return on equity | 37.60% |
| Return on investment | 28.25% |
More ▼
Cash flow in EURView more
In 2023, cash reserves at Orion Oyj fell by 225.90m. However, the company earned 119.00m from its operations for a Cash Flow Margin of 10.00%. In addition the company used 108.40m on investing activities and also paid 243.20m in financing cash flows.
| Cash flow per share | 2.78 |
|---|---|
| Price/Cash flow per share | 16.06 |
| Book value per share | 6.58 |
|---|---|
| Tangible book value per share | 5.10 |
More ▼
Balance sheet in EURView more
| Current ratio | 2.42 |
|---|---|
| Quick ratio | 1.41 |
| Total debt/total equity | 0.2778 |
|---|---|
| Total debt/total capital | 0.2174 |
More ▼
Growth rates in EUR
Year on year, growth in dividends per share increased 1.25% while earnings per share excluding extraordinary items fell by -37.87%. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked the highest relative to its industry peers.
| Div yield(5 year avg) | 3.75% |
|---|---|
| Div growth rate (5 year) | 1.55% |
| Payout ratio (TTM) | 34.26% |
| EPS growth(5 years) | 1.94 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 90.56 |
More ▼
